Package Leaflet: Information for the User
Caspofungin Demo 50 mg powder for concentrate for solution for infusion EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the package leaflet
5 Storage of Caspofungin Demo
What is caspofungin
Caspofungin Demo contains a medicine called caspofungin. This belongs to a group of medicines called antifungals.
What is caspofungin used for
Caspofungin is used to treat the following infections in children, adolescents, and adults:
This infection is caused by fungal cells (yeasts) called Candida. People who may get this type of infection include those who have just had an operation or those whose immune system is weakened. Fever and chills that do not respond to antibiotic treatment are the most common symptoms of this type of infection.
People who may get this type of infection include those who are receiving chemotherapy, those who have had a transplant, and those whose immune system is weakened.
How caspofungin works
Caspofungin makes the fungal cells fragile and prevents the fungus from growing properly. This prevents the infection from spreading and gives the body's natural defenses a chance to get rid of the infection completely.
Do not use caspofungin
If you are not sure, talk to your doctor, pharmacist, or nurse before you start using your medicine.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using caspofungin if:
If any of the above applies to you (or if you are not sure), talk to your doctor, pharmacist, or nurse before you start using caspofungin.
Caspofungin can also cause severe skin reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
Other medicines and Caspofungina Demo
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because caspofungin can affect how other medicines work. Also, other medicines can affect how caspofungin works.
Tell your doctor, pharmacist, or nurse if you are taking any of the following medicines:
If any of the above applies to you (or if you are not sure), talk to your doctor, pharmacist, or nurse before you start using caspofungin.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
There is no information to suggest that this medicine affects your ability to drive or use machines.
Caspofungin will always be prepared and given to you by a healthcare professional. You will be given caspofungin:
Your doctor will decide how long you should receive caspofungin and how much you should receive each day. Your doctor will monitor whether the effect of the medicine is adequate. If you weigh more than 80 kg, you may need a different dose.
Use in children and adolescents
The dose for children and adolescents may be different from the dose for adults.
If you use more caspofungin than you should
Your doctor will decide how much caspofungin you need and for how long each day. If you are worried that you have been given too much caspofungin, tell your doctor or nurse straight away.
In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse straight away if you notice any of the following side effects – you may need urgent medical treatment:
As with any prescription medicine, some side effects can be serious. Ask your doctor for more information.
Other side effects in adults include:
Common: may affect up to 1 in 10 people:
Uncommon: may affect up to 1 in 100 people:
Other side effects in children and adolescents
Very common: may affect more than 1 in 10 people:
Common: may affect up to 1 in 10 people:
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date is the last day of the month stated.
Store in a refrigerator (between 2°C and 8°C). Also, keep below 25°C for 1 month.
Once Caspofungin Demo has been prepared, it should be used immediately. This is because it does not contain any ingredients to prevent the growth of bacteria. Only a trained healthcare professional who has read the complete instructions should prepare the medicine (see “Instructions for reconstituting and diluting Caspofungin Demo” below).
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Caspofungin Demo.
Appearance of the product and container contents
This medication is a compact, sterile, white to off-white powder, contained in a 10 ml capacity transparent and colorless glass vial (type I), closed with a rubber stopper and sealed with an aluminum cap.
Each container contains one vial of powder.
Marketing authorization holder and manufacturer
DEMO S.A. PHARMACEUTICAL INDUSTRY
21st Km National Road Athens-Lamia.
14568 Greece
T:+30 210 8161802, F:+30 210816158
This medication is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Cyprus: Caspofungin DEMO 50 mg Powder for concentrate for solution for infusion
Germany: Caspofungin DEMO 50 mg Powder for concentrate for solution for infusion
Greece: Caspofungin DEMO 50 mg Powder for concentrate for solution for infusion
Ireland: Caspofungin 50 mg powder for concentrate for solution for infusion
United Kingdom: Caspofungin 50 mg powder for concentrate for solution for infusion
Netherlands: Caspofungine DEMO 50 mg powder for concentrate for solution for infusion
Spain: Caspofungina DEMO 50 mg powder for concentrate for solution for perfusion EFG
Romania: Caspofungina DEMO 50 mg powder for concentrate for solution for perfusion
Czech Republic: Caspofungin DEMO
Slovakia: Caspofungin DEMO 50 mg powder for concentrate for solution for infusion
Hungary: Caspofungin DEMO 50 mg powder for concentrate for solution for infusion
Finland: Caspofungin Demo S.A. 50 mg dry substance for intermediate concentrate for infusion solution, liquid
Sweden: Caspofungin Demo S.A.
Denmark: Caspofungin Demo S.A.
Norway: Caspofungin Demo S.A.
Poland: Caspofungin DEMO
Italy: Caspofungin DEMO 50 mg
Date of the last revision of this prospectus: 10/2024
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS): http://www.aemps.gob.es/
<-------------------------------------------------------------------------------------------------------------->
This information is intended only for healthcare professionals:
Instructions for reconstituting and diluting Caspofungina Demo:
Reconstitution of Caspofungina Demo
DO NOT USE DILUENTS CONTAINING GLUCOSE, as Caspofungina Demo is not stable in diluents containing glucose. DO NOT MIX OR INFUSE Caspofungina Demo WITH ANY OTHER MEDICATION, as there is no data available on the compatibility of caspofungin with other substances, additives, or pharmaceutical specialties for intravenous use. The infusion solution should be visually inspected for particulate matter or a change in color.
Preparation of the diluted solution before infusion
Caspofungina Demo can be administered in the following infusion solutions:
INSTRUCTIONS FOR USE IN ADULT PATIENTS
Step 1 Reconstitution of the vials
To reconstitute the powder, bring the vial to room temperature and add 10.5 ml of water for injectable preparations aseptically. The concentration of the reconstituted vial will be 5.2 mg/ml.
The compact, lyophilized, white to off-white powder will dissolve completely. Mix gently until a clear solution is obtained. The reconstituted solutions should be visually inspected for particulate matter or a change in color. The reconstituted solution can be stored for a maximum of 24 hours at a temperature equal to or below 25 °C.
Step 2 Addition of reconstituted Caspofungina Demo to the patient's infusion solution
The diluents for the final infusion solution are: sodium chloride injection solution or Ringer's lactate solution. The infusion solution is prepared by adding the appropriate amount of reconstituted concentrate (as shown in the following table) to a 250 ml infusion bag or bottle aseptically. Reduced-volume infusions of 100 ml can be used if medically necessary for daily doses of 50 mg or 35 mg. Do not use if the solution is cloudy or has precipitated.
PREPARATION OF THE INFUSION SOLUTION IN ADULTS
DOSE* | Volume of reconstituted caspofungina to transfer to an intravenous bag or bottle | Standard preparation (reconstituted caspofungina added to 250 ml) final concentration | Reduced-volume infusion (reconstituted caspofungina added to 100 ml) final concentration |
50 mg | 10 ml | 0.20 mg/ml | - |
50 mg in reduced volume | 10 ml | - | 0.47 mg/ml |
35 mg for moderate hepatic impairment (from a 50 mg vial) | 7 ml | 0.14 mg/ml | - |
35 mg for moderate hepatic impairment (from a 50 mg vial) in reduced volume | 7 ml | - | 0.34 mg/ml |
*10.5 ml should be used for the reconstitution of all vials.
INSTRUCTIONS FOR USE IN PEDIATRIC PATIENTS
Calculation of body surface area (BSA) for pediatric dosing
Before preparing the infusion, calculate the body surface area (BSA) of the patient using the following formula: (Mosteller's formula[1])
BSA (m2) =
Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17):1098 (letter)
Preparation of the 70 mg/m2 infusion for pediatric patients over 3 months (using a 50 mg vial)
BSA (m2) X 70 mg/m2 = loading dose
The maximum loading dose on day 1 should not exceed 70 mg, regardless of the calculated dose for the patient.
Preparation of the 50 mg/m2 infusion for pediatric patients over 3 months (using a 50 mg vial)
BSA (m2) X 50 mg/m2 = daily maintenance dose
The daily maintenance dose should not exceed 70 mg, regardless of the calculated dose for the patient.
[1]